Cologne

• A Randomized, Placebo-controlled, Double-blind, Parallel group, 6 Month Study to Evaluate the Safety, Tolerability, and Potential Efficacy o … Not authorised
  2022-500828-30-00 4 Early Alzheimer´s Disease
• Phase 2 Open Label Prospective Dose-Ranging Clinical Trial with Escalation and Expansion Cohorts to Evaluate Safety, Tolerability, Pharmacok … Not authorised
  2024-510582-42-00 4 Acute graft versus host disease (aGvHD)
• A prospective, open-label, randomized, multicenter phase-III trial to evaluate the efficacy of pirtobrutinib and epcoritamab compared with R … Pending
  2024-513445-37-00 5 previously untreated RT, irrespective of risk factors and disease stag
• SIOP PNET 5 medulloblastoma Pending
  2024-513724-42-00 10 Medulloblastoma
• A study to find an efficacious and safe dose of CHF10067 (zampilimab) in participants with idiopathic pulmonary fibrosis Pending
  2024-514246-37-00 4 Idiopathic pulmonary fibrosis (IPF)
• A study to evaluate the efficacy of oxaliplatin- or gemcitabine-based chemotherapy after allocation by standard criteria or by genetic marke … Pending
  2024-514682-19-00 5 Resected pancreatic ductal adenocarcinoma
• An open-label dose escalation study to estimate maximum tolerated dose (MTD), identify dose-limiting toxicities (DLTs) and study pharmacokin … Pending
  2024-515128-35-00 1 Glioblastoma
• Long-term impact of GBCAs on motor and cognitive function following repeated Contrast-Enhanced MRI—ODYSSEY Pending
  2024-515462-14-00 6 Long term potential effect of repeated exposure to either a linear or
• NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing sacituzumab govitecan+pembrolizumab vs. SoC chemotherapy in clinical st … Pending
  2024-516734-35-00 5 triple-negative early breast cancer
• Comparison of neurocognitive outcome in two standard regimen for treatment of low-risk medulloblastoma (COGNITO-MB) Pending
  2024-517133-40-00 5 newly diagnosed, non-metastatic, SHH-activated, TP53-wt, non-MYC ampli
• Prospective multicenter clinical trial for risk estimation and treatment stratification in low and intermediate risk neuroblastoma patients … Pending
  2024-517295-37-00 5 low and intermediate risk neuroblastoma
• Study to Investigate the Efficacy, Safety, and Tolerability of Intravenous Gammagard Liquid (Immune Globulin Infusion, 10%) for Primary Infe … Pending
  2024-518420-80-00 5 Primary infection prophylaxis for secondary immunodeficiency (SID) in
• A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease Pending
  2025-521113-13-00 10 Early Parkinson’s Disease
• Randomized, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab and Docetaxel Versus Docetaxel Monotherapy in Participants With Ad … Pending
  2025-521221-32-00 5 Advanced or Metastatic Non-Small Cell Lung Cancer
• IZABRIGHT-Lung01: Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after … Pending
  2025-521908-22-00 10 EGFR-mutated Non-small Cell Lung Cancer
• A study of Mirdametinib in Infants and Toddlers under 24months of age with Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas … Pending
  2025-522000-24-00 3 Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)
• Study of the safety and efficacy of asciminib in pediatric and young adult participants with r/r Ph+ or ABL-class Ph-like ALL Pending
  2025-522019-40-00 9 relapsed or refractory BCR::ABL1-positive (Philadelphia positive, Ph+)
• Use of the chemotherapy FOLFIRI and cetuximab if given with treatment breaks or continuously in patients with newly diagnosed metastatic col … Pending
  2025-522377-12-00 5 metastatic colorectal cancer
• OLISENS-ANIRIDIA Pending
  2025-522609-39-00 4 Corneal Neovascularization in Aniridia-associated Keratopathy
• A Study to Test How Well ZL-1310 may Work Compared to Therapies Selected by the Investigator in Treating Patients with Relapsed Small Cell L … Pending
  2025-522818-23-00 5 Small Cell Lung Cancer (SCLC)
• A Study of Vepugratinib (LY3866288) in Participants with Cancer in the Urinary Tract ( FORAGER-2 ) Pending
  2025-522855-25-00 5 Urinary Bladder Neoplasms
• A study to investigate the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of a CD19/CD20 T-cell engager in participants with … Pending
  2025-522932-15-00 3 Systemic Lupus Erythematosus
• A study testing the medicine angiotensin II in patients of 0–17 years with a life-threateningly low blood pressure Pending
  2025-523750-14-00 5 refractory hypotension in distributive shock
• A pivotal study of N-Acetyl-L-Leucine on CACNA1A Disorders Pending
  2025-523828-51-00 5 CACNA1A Disorders

Showing 1–24 of 577 trials